Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ArmonAir RespiClick
- Development stage
- Unknown
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Inhalation
01
Overview
ArmonAir RespiClick (fluticasone propionate MDPI) is an inhaled corticosteroid (ICS) monotherapy developed by Teva for the maintenance treatment of asthma in adolescent and adult patients. It is delivered via Teva's proprietary RespiClick device, which is a breath-actuated, multi-dose dry powder inhaler (MDPI) designed to eliminate the need for hand-breath coordination during inhalation. The active ingredient, fluticasone propionate, is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. It functions as an agonist at the glucocorticoid receptor, leading to the inhibition of multiple inflammatory cell types (such as mast cells, eosinophils, and lymphocytes) and the secretion of mediators (such as histamine and cytokines) involved in the asthmatic response. By reducing airway inflammation and hyperresponsiveness, it helps prevent asthma symptoms and exacerbations.
- Brand names
- ArmonAir RespiClickAermony Respiclick
- Other names
- fluticasone propionate MDPIfluticasone propionate multidose dry powder inhalerfluticasone propionate inhalation powder
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on ArmonAir RespiClick.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ArmonAir RespiClick.